CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900

We determined the prognostic relevance of CD25 (IL-2 receptor-α) expression in 657 patients (≤ 60 years) with de novo acute myeloid leukemia (AML) treated in the Eastern Cooperative Oncology Group trial, E1900. We identified CD25(POS) myeloblasts in 87 patients (13%), of whom 92% had intermediate-ri...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gönen, Mithat, Sun, Zhuoxin, Figueroa, Maria E., Patel, Jay P., Abdel-Wahab, Omar, Racevskis, Janis, Ketterling, Rhett P., Fernandez, Hugo, Rowe, Jacob M., Tallman, Martin S., Melnick, Ari, Levine, Ross L., Paietta, Elisabeth
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2012
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3447784/
https://ncbi.nlm.nih.gov/pubmed/22855599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-02-414425
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados